These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29521484)

  • 1. Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Esteve-Palau E; Grau S; Herrera S; Sorlí L; Montero M; Segura C; Durán X; Horcajada JP
    Rev Esp Quimioter; 2018 Apr; 31(2):110-117. PubMed ID: 29521484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study.
    Esteve-Palau E; Solande G; Sánchez F; Sorlí L; Montero M; Güerri R; Villar J; Grau S; Horcajada JP
    J Infect; 2015 Dec; 71(6):667-74. PubMed ID: 26380898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Tüzün T; Sayın Kutlu S; Kutlu M; Kaleli İ
    Turk J Med Sci; 2019 Aug; 49(4):1206-1211. PubMed ID: 31385490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
    Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
    J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
    Meier S; Weber R; Zbinden R; Ruef C; Hasse B
    Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance.
    Albaramki JH; Abdelghani T; Dalaeen A; Khdair Ahmad F; Alassaf A; Odeh R; Akl K
    Pediatr Int; 2019 Nov; 61(11):1127-1132. PubMed ID: 31206219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective cohort study of risk factors for extended-spectrum ß-lactamase-producing Escherichia coli urinary tract infections in elderly patients admitted to hospital.
    Artero A; Esparcia A; Alberola J; Madrazo M; Nogueira JM; Eiros JM
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28873266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis.
    Peñalva G; Fernández-Urrusuno R; Turmo JM; Hernández-Soto R; Pajares I; Carrión L; Vázquez-Cruz I; Botello B; García-Robredo B; Cámara-Mestres M; Domínguez-Camacho JC; Aguilar-Carnerero MM; Lepe JA; de Cueto M; Serrano-Martino MC; Domínguez-Jiménez MC; Domínguez-Castaño A; Cisneros JM;
    Lancet Infect Dis; 2020 Feb; 20(2):199-207. PubMed ID: 31767423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
    Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.
    Halldórsdóttir AM; Hrafnkelsson B; Einarsdóttir K; Kristinsson KG
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1689-1697. PubMed ID: 38935227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features of Febrile Urinary Tract Infection Caused by Extended-spectrum Beta-lactamase-producing Escherichia Coli in Children.
    Ohnishi T; Mishima Y; Takizawa S; Tsutsumi K; Amemiya A; Akiyama N; Kanna Y; Asato S; Tomita M; Ikemiyagi M; Shikoro N; Nakazawa M; Kurihara N; Kamimaki I
    Keio J Med; 2020 Jun; 69(2):43-47. PubMed ID: 31474677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
    Marković T; Jeinić L; Smitran A; Petković M
    Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on extended-spectrum β-lactamase producing Escherichia coli in urinary tract and blood stream infections: results from a nationwide surveillance network, Finland, 2018 to 2022.
    Ilmavirta H; Ollgren J; Räisänen K; Kinnunen T; Hakanen AJ; Rantakokko-Jalava K; Jalava J; Lyytikäinen O
    Antimicrob Resist Infect Control; 2024 Jul; 13(1):72. PubMed ID: 38971782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Cho SY; Choi SM; Park SH; Lee DG; Choi JH; Yoo JH
    Korean J Intern Med; 2016 Jan; 31(1):156-61. PubMed ID: 26767869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.